Related Experiment Videos
The hypoxia signalling pathway in haematological malignancies
Marta Irigoyen1, Juan Carlos García-Ruiz2, Edurne Berra1
1Centro de Investigación Cooperativa en Biociencias CIC bioGUNE, Derio, Spain.
Oncotarget
|April 19, 2017
Summary
Hypoxia, a low-oxygen state, is crucial in haematological malignancies, driving cancer stem cell resistance and treatment failure. Understanding hypoxia-inducible factors is key to overcoming therapy resistance in these blood cancers.
Area of Science:
- Oncology
- Hematology
- Cancer Biology
Background:
- Haematological malignancies impact blood and lymphatic systems, with significant challenges in therapy resistance and relapse.
- Cancer stem cells within the tumor microenvironment contribute to drug resistance.
- Hypoxia, previously linked to solid tumors, is now recognized as a key factor in the hematopoietic niche.
Purpose of the Study:
- To review the current understanding of hypoxia's role in haematological malignancies.
- To explore the involvement of hypoxia-inducible factors in blood cancer progression and treatment resistance.
Main Methods:
- Literature review of studies on hypoxia and haematological malignancies.
- Analysis of the impact of hypoxia-inducible factors on cancer stem cells and tumor aggressiveness.
Main Results:
- Hypoxia is a significant characteristic of the hematopoietic niche.
- Hypoxia-inducible factors are implicated in promoting aggressiveness, metastasis, and relapse in haematological cancers.
- The role of hypoxia in these non-solid tumors is increasingly recognized, challenging previous assumptions.
Conclusions:
- Hypoxia and hypoxia-inducible factors play a critical role in the pathogenesis and treatment resistance of haematological malignancies.
- Further research into targeting hypoxia pathways may offer new therapeutic strategies for blood cancers.